[go: up one dir, main page]

UY31521A1 - Nanoparticulas poliméricas solidas funcionalizadas que comprenden epotilonas - Google Patents

Nanoparticulas poliméricas solidas funcionalizadas que comprenden epotilonas

Info

Publication number
UY31521A1
UY31521A1 UY31521A UY31521A UY31521A1 UY 31521 A1 UY31521 A1 UY 31521A1 UY 31521 A UY31521 A UY 31521A UY 31521 A UY31521 A UY 31521A UY 31521 A1 UY31521 A1 UY 31521A1
Authority
UY
Uruguay
Prior art keywords
epotilones
functioned
solid
polymer nanoparticles
encapsulated
Prior art date
Application number
UY31521A
Other languages
English (en)
Spanish (es)
Inventor
Dr Sascha General
Dr Katrim Fischer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31521A1 publication Critical patent/UY31521A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UY31521A 2007-12-10 2008-12-09 Nanoparticulas poliméricas solidas funcionalizadas que comprenden epotilonas UY31521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007059752A DE102007059752A1 (de) 2007-12-10 2007-12-10 Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone

Publications (1)

Publication Number Publication Date
UY31521A1 true UY31521A1 (es) 2009-08-03

Family

ID=40409013

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31521A UY31521A1 (es) 2007-12-10 2008-12-09 Nanoparticulas poliméricas solidas funcionalizadas que comprenden epotilonas

Country Status (7)

Country Link
AR (1) AR069638A1 (fr)
DE (1) DE102007059752A1 (fr)
PA (1) PA8806901A1 (fr)
PE (1) PE20091107A1 (fr)
TW (1) TW200932220A (fr)
UY (1) UY31521A1 (fr)
WO (1) WO2009074274A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206747B2 (en) 2008-06-16 2012-06-26 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005725A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d’utilisation associés
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es) 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
JP5663741B2 (ja) * 2009-03-03 2015-02-04 株式会社ナノカム アミノ酸抱合シアノアクリレートポリマー粒子
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
JP5898627B2 (ja) * 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
CA2799202C (fr) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions et procedes de traitement de maladies auto-immunes et autres
US9610367B2 (en) 2010-08-24 2017-04-04 Canon Kabushiki Kaisha Particle and contrast agent having the particle
JP6356678B2 (ja) 2012-09-17 2018-07-11 ファイザー・インク 治療用ナノ粒子を製造する方法
CA2931547A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymeres, et compositions et procedes les impliquant
BR112016021130A2 (pt) 2014-03-14 2017-08-15 Pfizer Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
CA2946807A1 (fr) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanocapsules de poly(2-cyanoacrylate d'alkyle) hautement chargees en medicament
DE102017100317A1 (de) 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostrukturiertes Trägersystem zum Gentransport
CN115078292B (zh) * 2021-03-10 2025-02-11 北京大学 一种水性超分子粘附材料及其制备方法
EP4577601A1 (fr) * 2022-08-22 2025-07-02 Agfa-Gevaert Nv Particules de résine composite absorbant la lumière infrarouge proche et rouge

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262030A (en) 1882-08-01 Wash-stand
US252028A (en) 1882-01-10 Alonzo s
US258286A (en) 1882-05-23 Fruit-drier
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
WO1990013256A1 (fr) * 1989-05-04 1990-11-15 Wisconsin Alumni Research Foundation Procede de localisation et de traitement de tumeurs a l'aide de nouveaux complexes
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2684103B1 (fr) 1991-11-22 1994-09-02 Centre Nat Rech Scient Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
EP1440973A3 (fr) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Dérivés d'épothilone, procédé de production et utilisation
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19728914A1 (de) 1997-07-07 1999-01-14 Basf Ag Metallisch gefärbte Polyamide
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
WO1999018934A1 (fr) * 1997-10-09 1999-04-22 Vanderbilt University Dispositif d'administration de microparticules ou de nanoparticules de polymeres
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (fr) 1998-06-22 1999-12-29 Novartis Ag Desmethylepothilones
SE517641C2 (sv) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
JP2000095758A (ja) 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU3156700A (en) 1999-02-18 2000-09-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
WO2000057874A1 (fr) 1999-03-29 2000-10-05 Bristol-Myers Squibb Co. Procede de preparation d'epothilones d'aziridinyle a partir d'epothilone d'oxiranyle
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
CA2425620A1 (fr) 1999-10-08 2001-04-19 The Scripps Research Institute Derives d'epothilone d'alkyle-13 inferieur
JP2004500388A (ja) 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002008440A2 (fr) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Procédé de fermentation pour épothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2005500974A (ja) 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
EP1358144B1 (fr) 2000-10-16 2006-12-27 R&D-Biopharmaceuticals Composants synthetiques i d'epothilone : acyloines et derives d'acyloine a substitution asymetrique, leur procede de production et procede de production d'epothilone et de derives d'epothilone
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP2029119A2 (fr) * 2006-06-08 2009-03-04 Bayer Schering Pharma Aktiengesellschaft Nanoparticules polymères solides fonctionnalisées pour applications diagnostiques et thérapeutiques

Also Published As

Publication number Publication date
AR069638A1 (es) 2010-02-10
TW200932220A (en) 2009-08-01
PE20091107A1 (es) 2009-08-29
PA8806901A1 (es) 2009-07-23
WO2009074274A1 (fr) 2009-06-18
DE102007059752A1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
UY31521A1 (es) Nanoparticulas poliméricas solidas funcionalizadas que comprenden epotilonas
WO2014009833A3 (fr) Modulateurs de trajet de complément et leurs utilisations
WO2014002051A3 (fr) Modulateurs de la voie du complément et leurs utilisations
WO2014002058A3 (fr) Modulateurs de la voie du complément et utilisations de ceux-ci
HK1206017A1 (en) Complement pathway modulators and uses thereof
WO2007141050A3 (fr) Nanoparticules polymères solides fonctionnalisées pour applications diagnostiques et thérapeutiques
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
HN2010002774A (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA
BR112012006635A2 (pt) partículas de fosfato de cálcio uniformes, rígidas, esféricas, nanoporosas carregadas de agente ativo e métodos de fazer e usar as mesmas
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
CO7141411A2 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
FR3007969B1 (fr) Distributeur d'une dose unitaire d'une substance active sous une forme galenique solide
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
EA201190168A1 (ru) Терапевтические применения фракций мастиковой смолы
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019